it’s official: a Phase III CT with RUTI will be launched!

Because besides a good product, money is needed.

The media published yesterday the entry of a new group (TGT)  in Archivel Farma (the biotech developing RUTI). TGT has bought the 41,8% of the company owned by Fons Innocat (managed by Highgrowth partners), Inversions Valor Afegit and Agora Invest, thus substituting the capital risk partners who leave with a multiple of 1,6 gain. TGT is a big company devoted to developing a portfolio of european cheeses and now being at the forefront of the Cheese Sector. Now both TGT and the founders (leaded by mr. Pepe Martinez) will have 49,2% of the company each, the remaining 1,6% being owned by the catalan pharmaceutical company Reig Jofré.

With an investment of 15M €, the clinical development of the vaccine is ensured, and a Phase III CT is already planned to be launched next year.

Do you want to read more about it?

TGT La Vanguardia (in catalan)

This entry was posted in Uncategorized and tagged , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s